| Product NDC: | 61703-303 |
| Proprietary Name: | CYTARABINE |
| Non Proprietary Name: | CYTARABINE |
| Active Ingredient(s): | 20 mg/mL & nbsp; CYTARABINE |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 61703-303 |
| Labeler Name: | Hospira Worldwide, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA072168 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19900831 |
| Package NDC: | 61703-303-46 |
| Package Description: | 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (61703-303-46) > 50 mL in 1 VIAL, PHARMACY BULK PACKAGE |
| NDC Code | 61703-303-46 |
| Proprietary Name | CYTARABINE |
| Package Description | 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (61703-303-46) > 50 mL in 1 VIAL, PHARMACY BULK PACKAGE |
| Product NDC | 61703-303 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | CYTARABINE |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 19900831 |
| Marketing Category Name | ANDA |
| Labeler Name | Hospira Worldwide, Inc. |
| Substance Name | CYTARABINE |
| Strength Number | 20 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |